Most people are looking at the vote, not at what the FDA said. Six of the 10 panelists said the safety data is not sufficient, but with more data, they think the vaccine will pass. The FDA wants to see this pass.
A lot of biotech companies end up partnering things for what look like good financial terms and then the product languishes somewhere on a shelf. So having a partner that's really dedicated to promoting the product is important.
It has been a historically tough sell in a traditional flu market. You need a prescription, you need to take it within 48 hours of symptoms and not all pharmacies stocked it.
